Comptroller General. A lengthy process that delays the availability of important new drugs. Report to the Subcommittee on Science, Research, and Technology, House Committee on Science and Technology of the United States. Washington, DC: General Accounting Office (HRD-80-64), 1980.
2.
BreckenridgeA.M.Assessment of new drugs; a clinical pharmacologist's view. Br Med J1980; 280: 1303–5.
3.
NestorJ.O.Letter to the editor. N Engl J Med1980; 303: 755.
